Drug Profile
Research programme: gentamicin derivatives - La Jolla
Alternative Names: LJPC 30Sa; LJPC 30Sb; LJPC-30SLatest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator Indiana University Research and Technology Corporation
- Developer Indiana University Research and Technology Corporation; La Jolla Pharmaceutical Company; University of Alabama at Birmingham
- Class Aminoglycosides; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Cystic fibrosis; Duchenne muscular dystrophy
Most Recent Events
- 22 Aug 2022 La Jolla Pharmaceutical Company has been acquired by Innoviva
- 28 Jun 2019 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Parenteral)